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Abstract
The 5-HT2C receptor has been implicated in mood and eating disorders. In general, it is accepted that 5-HT2C receptor agonists
increase anxiety behaviours and induce hypophagia. However, pharmacological analysis of the roles of these receptors is hampered
by the lack of selective ligands and the complex regulation of receptor isoforms and expression levels. Therefore, the exact role of 5-
HT2C receptors in mood disorders remain controversial, some suggesting agonists and others suggesting antagonists may be
efficacious antidepressants, while there is general agreement that antagonists are beneficial anxiolytics. In order to test the
hypothesis that increased 5-HT2C receptor expression, and thus increased 5-HT2C receptor signalling, is causative in mood
disorders, we have undertaken a transgenic approach, directly altering the 5-HT2C receptor number in the forebrain and evaluating
the consequences on behaviour. Transgenic mice overexpressing 5-HT2C receptors under the control of the CaMKIIa promoter
(C2CR mice) have elevated 5-HT2C receptor mRNA levels in cerebral cortex and limbic areas (including the hippocampus and
amygdala), but normal levels in the hypothalamus, resulting in > 100% increase in the number of 5-HT2C ligand binding sites in the
forebrain. The C2CR mice show increased anxiety-like behaviour in the elevated plus-maze, decreased wheel-running behaviour and
reduced activity in a novel environment. These behaviours were observed in the C2CR mice without stimulation by exogenous
ligands. Our findings support a role for 5-HT2C receptor signalling in anxiety disorders. The C2CR mouse model offers a novel and
effective approach for studying disorders associated with 5-HT2C receptors.
Introduction
Central serotonergic systems modulate many behavioural and physi-
ological functions, and thus 5-HT receptors have attracted much
attention as therapeutic targets for various disorders (Barnes & Sharp,
1999). The 5-HT2C receptor is one of the 14 members of the 5-HT
receptor family (Martin & Humphrey, 1994), and its expression level is
particularly high in the limbic system and hypothalamus where its
activity is implicated in anxiety, depression, sleep disturbance,
locomotor activity and feeding behaviour as well as modulation of
pituitary release of ACTH and prolactin (Millan, 2005). Furthermore,
mice which lack 5-HT2C receptors are reported to be hyperphagic (they
develop obesity in later life) and hyperactive (Tecott et al., 1995), and
to demonstrate less anxiety-like behaviour (Heisler et al., 2007b).
Studies of 5-HT2C receptor function and its pathophysiological
role(s) have been difﬁcult, largely due to a lack of selective
pharmacological agents together with the complex regulation of
receptor density and activity. A nonselective 5-HT receptor agonist,
1-(m-chlorophenyl)-piperazine (mCPP), which shows preferential
afﬁnity at 5-HT2C receptors, has been used for inferring the role of
5-HT2C receptors. In rodents, mCPP induces anxiety (Cornelio &
Nunes-de-Souza, 2007; Hackler et al., 2007), inhibits locomotor
activity (Stiedl et al., 2007) and reduces food intake (Kennett &
Curzon, 1988; Hewitt et al., 2002). However, careful analyses are
required for such effects as mCPP also activates other 5-HT receptor
subtypes to regulate activity and food intake (Nonogaki et al., 2003;
Dalton et al., 2004; Lee et al., 2004). In addition, more recently
available 5-HT2C receptor agonists, such as RO 60-0175, have been
shown to exert a degree of action on other 5-HT2 receptor subtypes
(Higgins et al., 2001; Damjanoska et al., 2003). Coupled with the lack
of selective ligands, there is disagreement in the literature over
whether it is the activation or inhibition of the 5-HT2C receptors that
causes anxiety or depressive behaviour, and hence whether it is the
agonists or antagonists that could be effective antidepressants (Millan
et al., 2005; Dunlop et al., 2006; Cremers et al., 2007).
Further complexity is introduced by RNA editing of the 5-HT2C
receptor transcript, which potently modulates both the degree of
constitutive activity of the encoded receptor and its sensitivity to
ligands (Burns et al., 1997). Moreover, the extent of editing is altered
in different mouse strains (Englander et al., 2005), following early-life
stress (Bhansali et al., 2007), following modulation of serotonergic
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neurotransmission (Gurevich et al., 2002a), or in post-mortem brains
from suicide victims (Gurevich et al., 2002b).
Here we have tested the hypothesis that elevated 5-HT2C receptor
density in forebrain alters behaviour. In order to circumvent the
problems associated with poor selectivity of pharmacological agents,
we have undertaken a transgenic approach: we have overexpressed
5-HT2C receptors in mouse forebrain and examined the resulting
phenotype. The CaMKIIa–5-HT2C receptor transgene promoting
overexpression only expresses the unedited isoform of the receptor;
consequently, the balance of the edited isoforms in our transgenic mice
will be modiﬁed considerably compared with wild-type mice. We
report the behavioural phenotype of transgenic mice with forebrain
overexpression of 5-HT2C receptors.
Materials and methods
Generation of transgenic mice overexpressing 5-HT2C receptors
in forebrain
The full length (unedited) rat 5-HT2C receptor cDNAwas ampliﬁed by
PCR from a plasmid template (pMV7-sr1cm; a gift from David Julius,
San Francisco, USA). An inﬂuenza haemagglutinin (HA) epitope tag
was added at the N-terminus of the receptor by subcloning a double-
stranded oligonucleotide encoding the HA tag at a KpnI site generated
by PCR at the translation start of the 5-HT2C receptor cDNA. Receptor
function is not altered by the N-terminal addition of this tag (Hurley
et al., 1999). The HA–5-HT2C receptor cDNAwas then subcloned into
theEcoRV site of pNN265 (Mayford et al., 1996). Transient transfection
of this plasmid into Cos7 cells conferred binding of the 5-HT2C receptor
ligand 3H-mesulergine (data not shown). ANot1 fragment including the
HA–5-HT2C receptor (HA-2CR) cDNAwas then inserted into the NotI
site of pMM403, encoding the mouse calcium–calmodulin-dependent
protein kinase (CaMK) IIa promoter (Mayford et al., 1996), to create the
transgene construct CaMKIIa–HA-2CR (Fig. 1A). All constructs were
veriﬁed by DNA sequencing. Transgenic mice were generated by
pronuclear injection of the 11-kb CaMKIIa–HA-2CR minigene
construct into C57BL ⁄ 6J · CBA embryos. Four founder mice (desig-
nated C2CR)were obtained, all of which transmitted the transgene. Two
C2CR lines (C2CR.10 and C2CR.33), which demonstrated similar
traits, were selected for further characterisation. Mice were backcrossed
to C57BL ⁄ 6 and they were genotyped by PCR using primers
corresponding to the HA tag (forward: 5¢-ATGTACCCATACGAT-
GTTCCAGATTACGCT-3¢) and complementary to the 5-HT2C recep-
tor cDNA (reverse: 5¢-CAGAGGTGCATGGACGC-3¢), giving a
product of 420 bp. In some experiments, genotypes were conﬁrmed
by Southern blot analysis of the EcoRV digested genomic DNA
from C2CR mice, probed with a 32P-labelled DNA fragment com-
prising the 2.7-kb BamH1 fragment of the transgene. Southern blotting
was also used to conﬁrm a single integration site of the transgene
in C2CR.10 and C2CR.33 mice, consistent with the observed 50%
transmission rate for the transgene. Experimental mice were F3–F5.
Fig. 1. Overexpression of 5-HT2C receptors in forebrain of CaMKIIa–2CR transgenic (C2CR) mice. (A) A schematic illustration of the transgene construct used for
overexpressing 5-HT2C receptors in forebrain; HA, haemagglutinin epitope tag. (B) Representative autoradiograph of mouse brains (control, C2CR.10 and C2CR.33)
showing 5-HT2C receptor mRNA levels and distribution detected by in situ mRNA hybridisation histochemistry. Extensive enhancement of 5-HT2C receptor mRNA
density was observed in the C2CR.33 mice and a more restricted increase (mainly in the dorsal hippocampus) of 5-HT2C receptor mRNA level was observed in the
C2CR.10 mice. (C) Elevated 5-HT2C receptor binding sites in the membrane fraction isolated from C2CR.33 mouse forebrain compared with the littermate controls
(n = 5–6; *P < 0.01). There was no difference between genotypes in the hindbrain membrane fraction. Data are mean ± SEM.
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Animals
Animals were given standard chow and water ad libitum, lights were
on between 07:00 h and 19:00 h, and all studies were performed to the
highest standards of humane animal care under the aegis of the United
Kingdom Animals Scientiﬁc Procedures Act, 1986. In all experiments,
nontransgenic littermates of the corresponding C2CR mice served as
controls. For in vitro experiments, male mice (30–35 g) were killed by
cervical dislocation and whole brain was immediately removed and
frozen on dry ice.
Detection of 5-HT2C receptor mRNA by in situ hybridisation
In situ mRNA hybridisation was performed as described previously
(Holmes et al., 1995, 1997). In brief, brain sections (15 lm) were
thaw-mounted on silane-coated slides and post-ﬁxed in 4% parafor-
maldehyde in a 0.1 m phosphate buffer followed by three washes in
PBS, then dehydrated in increasing concentrations of ethanol. Sections
were incubated in a prehybridisation buffer (deionised formamide,
50%; NaCl, 600 mm; Tris–HCl, pH 7.5, 10 mm; EDTA, 1 mm;
1 · Denhardt’s solution; salmon sperm DNA, 0.5 mg ⁄mL; and yeast
tRNA, 0.1 mg ⁄mL) for 2 h at 50C. [35S]-UTP-labelled probe for
detecting endogenous 5-HT2C receptors (complementary to the
5¢-UTR, absent from the transgene) was prepared as described
previously (Holmes et al., 1997). Transgene expression was detected
with a [35S]-UTP labelled HA-2CR riboprobe corresponding to the
HA tag and ﬁrst 400 bp following the translation start of the rat
5-HT2C receptor cDNA. This riboprobe also hybridises to the
endogenous 5-HT2C receptor mRNA. [
35S]-UTP-labelled probes
(107 cpm ⁄mL) were hybridised to brain sections and stringent washes
were carried out as described previously (Holmes et al., 1995). Brain
sections were exposed to a Kodak BioMax MR ﬁlm (Sigma-Aldrich,
Poole, UK) for 3–8 days, and optical density for the area of interest
was measured using an image analysis software MCID-M4, ver 3.0,
rev.1.5 (Interfocus Imaging Ltd, Cambridge, UK). Data are expressed
as percentages of values in control animals.
Radioligand binding assay for 5-HT2C receptors
Radioligand binding assays for 5-HT2C receptors were carried out as
described previously (Marazziti et al., 1999), with slight modiﬁca-
tions. In brief, forebrains or hindbrains from C2CR and control mice
(frozen on dry ice and stored at )80C until use) were homogenised in
a buffer containing 0.32 m sucrose, 50 mm Tris–HCl (pH 7.4),
0.1% ascorbate and protease inhibitors (Mini Protease inhibitor
cocktail tablets, Roche Applied Science, West Sussex, UK), then
centrifuged at 300 g for 5 min at 4C. The supernatant was removed
and centrifuged at 50 000 g for 15 min at 4C. The resulting pellet
was washed and resuspended in an ice-cold buffer containing 50 mm
Tris–HCl (pH 7.4), 0.1% ascorbate and protease inhibitors, for use in
the assay. Total binding in membranes (0.6 mg ⁄mL protein) was
determined in the presence of 10 nm 3H-mesulergine (speciﬁc activity:
2.85 Tbq ⁄mm; GEHealthcare, Amersham, UK) and 100 nm spiperone
(Sigma), for blocking 3H-mesulergine binding to 5-HT2A receptors,
while nonspeciﬁc binding was determined with an addition of 1 mm
5-HT (Sigma). The membranes were incubated with the aforemen-
tioned ligands, as appropriate, for 30 min at 37C. Membrane
incubation was terminated by rapid ﬁltration using a Combi cell
harvester (Skatron Instruments, Lier, Norway), ﬁlters were washed and
dried, and then the radioactivity remaining on the ﬁlters was quantiﬁed
using a liquid scintillation counter (Packard tri-carb 2100TR, Packard
Instruments, Berks, UK).
Measurement of activity in wheel-running test
Male C2CR and control mice were individually housed in wheel cages
(wheel diameter of 23.5 cm) and wheel revolutions were counted
using Clocklab acquisition and analysis computer software (ActiMet-
rics, IL, USA) throughout the whole experimental period. Average
daily revolutions were calculated over a 7-day period, following a
5-day acclimatisation period. Activity of mice during the ﬁrst 1–2 h
from the start of dark phase (i.e. 19:00–21:00 h) was recorded to
determine the phenotypic and drug-induced effects.
Behavioural tests
For the elevated plus-maze (EPM) and open-ﬁeld tests, male C2CR
and control mice were individually caged 48 h prior to the tests, then
moved from the holding room to the behaviour room 2 h prior to the
tests for acclimatisation. Each mouse undertook up to three behavio-
ural tests in random order with an interval of 1 week between tests,
except when they were scheduled for the EPM test. The EPM test was
always carried out ﬁrst as the behaviour in this test was inﬂuenced by
the pre-exposure to other behavioural tests (data not shown). Mice and
drug treatments used in the behavioural tests were randomised in a
double-blind manner.
Open-field test
The open-ﬁeld test was performed as described previously (Holmes
et al., 2006). In brief, the open-ﬁeld arena consisted of a square box
(50 · 50 cm, 25 cm high, grey Perspex) divided into 5 · 5 grids, with
the central nine squares deﬁned as the inner zone and the rest as the
outer zone. A male C2CR or control mouse was placed in a corner of
the box and its activity was monitored and recorded for 5 min using a
computer tracking system, Limelight (ActiMetrics, IL, USA). The
number of crossings into the inner zone, time spent in the inner zone
and distance travelled within the inner zone were analysed.
EPM test
The EPM test was performed as described previously (Holmes et al.,
2006). In brief, the maze consisted of a perspex platform in a shape of
a plus sign, raised 1 m above ground. One opposing pair of arms was
enclosed by high walls (closed arms) and the other opposing arms
were exposed (open arms). A male C2CR or control mouse was placed
in the centre of the plus-maze, where all the arms met, and its
behaviour was monitored and recorded immediately thereafter for
5 min using a computer tracking system (Limelight). The number of
open-arm entries, time spent in the open arms and distance travelled
within the open arms were analysed. Ethological parameters such as
stretch–attend (stretching out from enclosed arms over the side of the
open arm), rearing, grooming, immobility and faeces were scored
manually.
Tail-suspension test
The tail-suspension test is used to determine depressive-like charac-
teristics, indicated by the time spent immobile during the test. A male
C2CR or control mouse was suspended above the table top using an
adhesive tape placed 0.5 cm from the tip of its tail. Total duration of
immobility was measured over a 6-min period. Mice were considered
to be immobile only when they hung down passively and were
completely motionless. Mice were scored every 5 s as either S
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(struggling) or H (hanging). Hanging-to-struggling ratios and the
percentage time spent hanging were also calculated.
Drug treatment
In order to elucidate the role of 5-HT2C receptors in the behavioural
tests, mice were injected with the following drugs: 5-HT receptor
agonists mCPP (0.3–3 mg ⁄ kg; Sigma) and (S)-2-(chloro-5-ﬂuoro-
indol- l-yl)-1-methylethylamine fumarate (RO 60-0175; 3–5 mg ⁄ kg;
Tocris Bioscience, Bristol, UK); the 5-HT2C receptor antagonist
6-chloro-5-methyl-1-[6-(2-methylpiridin-3-yloxy)pyridin-3-yl carba-
moyl] indoline (SB242084; 3 mg ⁄ kg; Sigma), the 5-HT2C receptor
inverse agonist 5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydro-
pyrrolo[2,3-f] indole hydrochloride (SB206553; 1–5 mg ⁄ kg; Tocris
Bioscience) or vehicle (10% ethanol in saline for all drugs except
mCPP and RO 60-0175, which were dissolved in saline). The drugs
were administered i.p. 30 min prior to testing or (for wheel-running
behaviour) 30 min prior to entering the dark phase (i.e. injected at
18:30 h).
Measurement of plasma corticosterone
For the measurement of basal plasma corticosterone, blood samples
were taken between 07:00 and 08:00 h, by tail venesection within
< 30 s after disturbing the mouse in its home cage. For peak stress
plasma samples, trunk blood was collected 10 min after a mouse was
placed in a Perspex restraint tube. Blood was collected in EDTA-
coated Microvette tubes (Sarstedt, Numbrecht, Germany) and centri-
fuged, and plasma was stored at )20C until corticosterone determi-
nation by radioimmunoassay as described previously (Holmes et al.,
1997).
Statistical analysis
The genotypic effect was analysed using a Student’s t-test. For the
behavioural studies, one- or two-way anova was used as appropriate,
followed by a Dunnett’s post hoc test. Data are expressed as the
mean ± SEM.
Results
Generation of transgenic mice overexpressing 5-HT2C receptors
in forebrain
Four lines of C2CR transgenic mice were generated following
pronuclear microinjection of a CaMKIIa–HA-2CR minigene
(Fig. 1A), in which the CaMKIIa promoter (forebrain-speciﬁc) drives
the expression of unedited 5-HT2C receptors. In order to facilitate
transgene detection, an HA epitope tag was added to the N-terminus of
the receptor, a modiﬁcation that does not affect receptor function
(Hurley et al., 1999).
All C2CR mouse lines were viable and healthy with normal body
weight and displayed no gross abnormalities (data not shown). The
average litter size and gender ratio were unaffected by the transgene
integration. Southern blotting conﬁrmed the transgene integration at a
single site (data not shown). Based on the expression pattern of the
transgene in the forebrain, two lines were selected for further
characterisation: C2CR.33, in which 5-HT2C receptor mRNA levels
are high and widely distributed throughout the forebrain including the
cerebral cortex, hippocampus and amygdala (Fig. 1B and Table 1),
and C2CR.10, in which the distribution of 5-HT2C receptor mRNA is
broadly similar to C2CR.33 but the level of overexpression is lower
than in C2CR.33 (Fig. 1B and Table 1). The level of endogenous
5-HT2C receptor mRNA expression in both C2CR mouse lines was
unaltered compared with the controls (data not shown). 3H-mesuler-
gine binding to forebrain membranes from C2CR.33 mice was over
two-fold greater than the controls (Fig. 1C), indicating the increased
5-HT2C receptor mRNA level was translated into higher receptor
levels at the cell surface. The level of 3H-mesulergine binding sites
was not altered in the hindbrain membranes where the transgene is not
expressed (Fig. 1C). Initial phenotypic characterisation was carried out
in both C2CR mouse lines and similar data were obtained despite the
differences in the transgene expression levels.
Reduced locomotor activity in C2CR mice
Daily wheel-running activity in the C2CR mice was signiﬁcantly
lower than in the control mice (Fig. 2A). Also, the distance travelled
by the C2CR mice in a novel environment (open ﬁeld) was
signiﬁcantly less than the controls (Fig. 2B). These results suggest
that an increased forebrain 5-HT2C receptor expression reduces
locomotor activity.
Table 1. 5-HT2C receptor mRNA expression in C2CR mouse brain
Brain area
5-HT2C receptor mRNA expression
(% of control mice)
C2CR.10 C2CR.33
Dorsal hippocampus
Dentate gyrus 20476 ± 1992** 3146 ± 369**
CA1 709 ± 80** 1688 ± 210**
CA3 633 ± 67** 2373 ± 319**
Cerebral Cortex 322 ± 84* 380 ± 42*
Amygdala 101 ± 9 250 ± 29*
Choroid plexus 105 ± 8 87 ± 9
The percentage change in 5-HT2C receptor mRNA expression in the C2CR
mouse brains (C2CR.10 and C2CR.33 mice) relative to the corresponding
control mice. The expression levels were determined by in situ hybridisation of
brain sections followed by densitometric analysis of autoradiographs exposed
to the hybridised brain sections. Data are mean ± SEM; n = 6; *P < 0.05,
**P < 0.001 compared with the control mouse brain.
Fig. 2. C2CR mice showed decreased activity. (A) Voluntary wheel-running
activity: mice were individually placed in a cage with free access to a running
wheel connected to a system for recording the number of wheel revolutions
(a measurement of activity levels). The average number of wheel revolutions
(over 7 days) generated by the C2CR mice was signiﬁcantly lower than for the
controls. (B) Open-ﬁeld (novel environment) test: mice were individually
placed in an open-ﬁeld arena and their movement monitored for 5 min. Total
distance travelled within the open-ﬁeld arena in the C2CR mice was
signiﬁcantly less than for the controls. White bar, control mice; black
bar, C2CR mice. Data are mean ± SEM; n = 6–8, *P < 0.05 genotypic
comparison.
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C2CR mice showed increased anxiety-like behaviour
The total distance travelled in the EPM was similar between genotypes
for both C2CR lines, indicating that this paradigm was unable to detect
the general hypolocomotor effects of the 5-HT2C receptor overexpres-
sion (data not shown). However, the distance travelled within the open
arms by the C2CR mice was signiﬁcantly less than by the controls
(Fig. 3A), indicating an increased anxiety-like behaviour in the C2CR
mice. Ethologically-derived behaviouralmeasures in this test showed no
signiﬁcant difference between genotypes for the number of stretch–
attends (out of the closed arms over the side of the open arms), rears,
faeces or bouts of grooming or immobility (data not shown). However,
the time spent investigating the open arms (stretch–attend), indicative of
a risk-assessment strategy, was signiﬁcantly greater in the C2CR mice
(19.8 ± 5.0 s, n = 10) than in the controls (8.3 ± 0.9 s, n = 9;
P = 0.04). Also, there was a tendency for the C2CR mice to spend
more time immobile during the test than did the controls (C2CR mice,
32.9 ± 16.5 s, n = 10; controls, 11.9 ± 7.1 s, n = 9; NS). Consistent
with the increased anxiety, in the open-ﬁeld test the C2CRmice showed
fewer crossings into the central area of the open-ﬁeld arena as a
percentage of total crossings than did the control mice (Fig. 3B).
In the tail-suspension test, there was no difference between the
genotypes for the depressive-like behaviour, indicated by the
percentage time spent hanging immobile (controls, 50.36 ± 2.64%,
n = 27; C2CR mice, 54.72 ± 2.21%, n = 20; NS), suggesting that
overexpression of 5-HT2C receptors in the forebrain does not induce a
depressive-like behaviour.
The increased anxiety-like behaviour was not accompanied by (or
could not be ascribed to) activation of the hypothalamic–pituitary–
adrenal (HPA) axis as plasma corticosterone levels were the same in
the C2CR and control mice, at both basal and stressed states (Table 2).
Furthermore, chronic alteration in the HPA axis activity is unlikely as
adrenal weights were also identical in the two genotypes (Table 2),
suggesting that there was no major modiﬁcation in the long-term
corticosterone secretion as a result of increased level of forebrain
5-HT2C receptors.
Effect of 5-HT2C receptor ligands on wheel-running behaviour
in C2CR mice
The hypolocomotor effects of transgene expression could be due to an
elevated forebrain 5-HT2C receptor number, an increased ligand
sensitivity of transgene-encoded 5-HT2C receptor (the unedited
isoform has a higher constitutive activity and an increased ligand
sensitivity in vitro) or a combination of the two. In order to address
this question, 5-HT2C receptor ligands or vehicle were administered to
the C2CR mice (i.p.) and effects on locomotor activity in wheel
running were measured for 2 h following the onset of the dark phase
(i.e. during the period 19:00–21:00 h). The C2CR mice showed
clearly a reduced activity compared with the controls in all conditions:
basal (no injection), or following saline or mCPP (3 mg ⁄ kg)
administration (F1.24 = 14.27, P < 0.001; Table 3). Administration
of mCPP decreased the wheel-running activity compared with the
saline injection alone by 64.4 ± 19.2% in the controls and by
79.6 ± 9.7% in the C2CR mice (n = 6). The effect of mCPP was
highly signiﬁcant (F2.24 = 29.0, P = 0.0001), but there was no
interaction of drug and genotype. A lower dose of mCPP (0.3 mg ⁄ kg)
had no effect in either genotype compared with the saline injection
(data not shown).
Fig. 3. C2CR mice showed increased anxiety-like behaviour. (A) EPM test:
mice were placed individually in the centre of the EPM and their movement
monitored for 5 min. The % distance travelled in the more anxiogenic open
arms in the C2CR mice (black bar) was signiﬁcantly lower than the controls
(white bar). (B) Open-ﬁeld test: mice were placed individually in one corner of
the open-ﬁeld arena and their movement monitored for 5 min. The ratio of
central to total crossings in the open-ﬁeld arena was used for quantifying the
anxiety component in this test. The percentage crossing into the more
anxiogenic central zone in the C2CR mice (black bar) was lower than for the
controls (white bar). Data are mean ± SEM; n = 8–11, *P < 0.05 genotypic
comparison.
Table 2. Basal and peak stress plasma corticosterone levels and adrenal
weights in C2CR mice
Control C2CR
Plasma corticosterone (nm)
Basal 58.3 ± 18.1 63.2 ± 8.1
Stress 257.0 ± 89.4* 254.3 ± 33.6*
Adrenal weight (mg) 0.6 ± 0.04 0.6 ± 0.01
Plasma corticosterone levels were determined in the C2CR and control mice at
two states: unstressed (basal) and stressed (after 10 min restraint). Stress was
applied using a restraint tube and the blood samples were collected once
between 07:00 h and 08:00 h. Stress increased plasma corticosterone levels in
both control and C2CR mice, but there was no genotypic difference. Adrenal
weights were almost identical in the control and C2CR mice. Data are
mean ± SEM; n = 6; *P < 0.01 compared with the respective basal levels.
Table 3. Effects of 5-HT2C receptor antagonist and inverse agonist on wheel-
running behaviour in C2CR mice
Treatment and time of day Control (revolutions) C2CR (revolutions)
Basal
19:00–20:00 h 5038 ± 318 3228 ± 912*
20:00–21:00 h 4405 ± 657 2379 ± 842
Vehicle
19:00–20:00 h 4462 ± 420 1523 ± 1050*
20:00–21:00 h 3791 ± 971 2603 ± 844
Antagonist SB242084 (3 mg ⁄ kg)
19:00–20:00 h 3751 ± 916 2093 ± 784*
20:00–21:00 h 3445 ± 1054 1671 ± 772
Inverse agonist SB206553 (1 mg ⁄ kg)
19:00–20:00 h 3149 ± 1175 1907 ± 681
20:00–21:00 h 3794 ± 913 1254 ± 570
Inverse agonist SB206553 (5 mg ⁄ kg)
19:00–20:00 h 1401 ± 440 351 ± 325*,
20:00–21:00 h 2074 ± 713 1097 ± 687
The number of wheel revolutions generated by the control and C2CR mice in
the 2 h subsequent to the lights being switched off were counted in untreated
mice (basal) and treated mice: 30 min following the administration of vehicle,
antagonist (SB242084; 3 mg ⁄ kg) or inverse agonist (SB206553; 1 or
5 mg ⁄ kg). While the C2CR mice generally carried out less wheel running than
the control mice (F1.50 = 13.0, P < 0.001), there were differences between the
treatment groups (F4.50 = 4.9, P < 0.01). However, the effect of the drug
treatment was similar across the genotypes (i.e. no interaction). Data are
mean ± SEM; n = 6; *P < 0.05 compared with the respective control mice;
P < 0.05 compared with the respective saline group.
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In order to further examine whether the reduced wheel-running
activity in the C2CR mice is due to higher sensitivity of the receptors
to endogenous 5-HT or increased constitutive receptor activity, a
selective antagonist (SB242084) or an inverse agonist (SB206553)
was injected 30 min prior to the onset of the dark phase. SB242084, at
doses previously shown to antagonise ligand-activated 5-HT2C
receptors in mouse (Stiedl et al., 2007), failed to affect the wheel-
running behaviour in both control and C2CR mice (Table 3). This
suggests the hypolocomotion in the C2CR mice may be due to
increased constitutive activity of overexpressed 5-HT2C receptors
rather than an increased ligand activation of 5-HT2C receptors by
endogenous 5-HT. Administration of SB206553 was expected to
antagonise the constitutive activity of 5-HT2C receptors and hence
increase locomotion, particularly in the C2CR mice. However,
SB206553 at higher doses (5 mg ⁄ kg, i.p.) paradoxically decreased
locomotion in both control and C2CR mice (Table 3). The speciﬁcity
of SB206553 for 5-HT2C receptors was tested by administration of this
drug to 5-HT2C receptor-deﬁcient mice, in which it also reduced
activity (M. C. Holmes, P. L. Stevenson and R. N. Carter, unpublished
data). This demonstrates that in mouse, contrary to rat, SB206553
inhibits locomotion through a mechanism distinct from the 5-HT2C
receptor signalling. Therefore, SB206553 was unable to elucidate the
constitutive activity of the 5-HT2C receptors in the C2CR mice.
Effect of 5-HT2C receptor agonists on locomotor behaviour
in the open-field test
In order to test the acute effect of 5-HT2C receptor agonists on
movement in a novel environment, locomotion was assessed in the
open-ﬁeld test. This test evaluates both locomotor activity and
anxiety-like behaviour. C2CR and control mice were injected with
saline or mCPP, 30 min prior to observation of activity in the open
ﬁeld. A two-way anova revealed that there was a signiﬁcant effect of
drug treatment on activity (F1.36 = 4.81, P = 0.03) but no effect of
genotype; however, there was a signiﬁcant interaction of the two
variables (F1.36 = 6.28, P = 0.017), indicating that the effect of mCPP
was dependent on genotype. When the C2CR and control mice were
analysed independently, compared with the saline treatment, mCPP
(0.3 mg ⁄ kg) signiﬁcantly reduced both the total distance travelled
(Fig. 4A) and the total number of crossings (data not shown) in the
control mice whereas it had no effect upon the activity of the C2CR
mice (Fig. 4A). In contrast, when the effect of RO 60-0175 (a more
selective agonist) was examined under the same conditions, RO
60-0175 inhibited locomotion in both control and C2CR mice
at 5 mg ⁄ kg, while only the C2CR mice were affected by the lower
dose (3 mg ⁄ kg; Fig. 4B).
Discussion
We have tested the hypothesis that increased 5-HT2C receptor
signalling may be causative of anxiety and reduced activity, and
provide a proof-of-principle that increased 5-HT2C receptor levels in
the forebrain alter behaviour. We have generated transgenic mice
whose forebrain 5-HT2C receptors are overexpressed. The transgene
expression in our transgenic (C2CR) mice was driven by the well-
characterised CaMKIIa promoter which increased the 5-HT2C receptor
levels in the limbic regions and cerebral cortex, a pattern of expression
that is similar (though not identical) to the endogenous 5-HT2C
receptor expression (Palacios et al., 1990; Holmes et al., 1995). The
C2CR mice demonstrated that forebrain 5-HT2C receptor overexpres-
sion results in hypolocomotion and increased anxiety-like behaviour.
The two C2CR mouse lines, one with high and the other with modest
levels of 5-HT2C receptor overexpression in the forebrain, showed a
consistent phenotype, suggesting that the observed phenotype is as
a result of the 5-HT2C receptor overexpression and is not due to a
disruption of an unknown gene by a random chromosomal insertion of
the transgene. There were no differences in the bodyweight or basal and
stress-induced plasma corticosterone levels between theC2CRmice and
their littermate controls. These results are consistent with the lack of
transgene expression of 5-HT2C receptors in the hypothalamic areas,
which is involved in regulation of feeding or indeed regulation of
corticotropin-releasing factor (Heisler et al., 2007a; Lam et al., 2008)
and, hence, involved in corticosterone production. Therefore, this
eliminates the possibility that the elevated anxiety-like behaviour in the
C2CR mice results from a hypersensitive HPA axis.
Our data show that elevated 5-HT2C receptors levels in the C2CR
mice generate anxiety-like behaviour in the absence of exogenous
ligand administration, suggesting that these receptors are already
activated by the endogenous ligand and ⁄ or they are constitutively
active. Our observation that the C2CR mice demonstrate greater
anxiety-like behaviour in the EPM test and in the open-ﬁeld test is
consistent with previous studies demonstrating that 5-HT2C receptor
agonists (i.e. increased 5-HT2C receptor signalling) elevate anxiety,
while the antagonists are anxiolytic (Kennett et al., 1989; Jenck et al.,
1998; Alves et al., 2004). Indeed, antagonists have shown not only
anxiolytic properties but also antidepressant properties (Millan et al.,
2005; Dekeyne et al., 2008). However, the antidepressant properties of
agomelatine (Millan et al., 2005) may in part be attributed to its
melatonin agonist activity. Conversely, 5-HT2C receptor agonists,
rather than antagonists, have also been demonstrated to be efﬁcacious
antidepressants (Dunlop et al., 2006). Interestingly, the C2CR mice do
not display depression-like behaviour in the tail-suspension test,
suggesting that increased signalling through 5-HT2C receptors does
not lead to depression. However, evaluation of more tests for
depression are warranted (prior to and following antidepressant
treatment) before a depressive-like state can be ruled out in these
transgenic mice.
Fig. 4. Effect of 5-HT2C receptor agonists on locomotor activity in 2CR mice
in a novel environment. (A) Distance travelled in the open-ﬁeld arena was
determined in control and C2CR mice following saline or mCPP (0.3 mg ⁄ kg)
injection (i.p.). The distance travelled by control mice was signiﬁcantly
decreased following the mCPP treatment. However, mCPP had no effect on the
distance travelled in C2CR mice compared with saline treatment. (B) The effect
of RO 60-0175 on the inhibition of activity in the open-ﬁeld test was compared
with the effect of saline alone in the control or C2CR mice. Mice were
administered RO 60-0175 (3 mg ⁄ kg, black bar; 5 mg ⁄ kg, striped bar) or
vehicle (open bar) i.p., 30 min prior to testing activity in the open-ﬁeld arena
for 5 min. The higher dose of RO 60-0175 (5 mg ⁄ kg) reduced the activity of
both control and C2CR mice, whereas the lower dose (3 mg ⁄ kg) was only
efﬁcacious in the C2CR mice. Data are mean ± SEM; n = 9–11; *P < 0.05
compared with saline in respective genotypes; **P < 0.05 compared to saline
injection in control mice.
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The C2CR mice were hypoactive in two different behavioural
paradigms: voluntary activity measured in wheel running and activity
assessed in a novel environment with a component of stress (open
ﬁeld). Hypoactivity is also observed in response to 5-HT2C receptor
agonists (Stiedl et al., 2007) underpinned by 5-HT2C receptor
regulation of dopamine release (Di Matteo et al., 1999, 2004;
De Deurwaerdere et al., 2004). 5-HT2C receptor agonists inhibit
mesocortical dopaminergic pathways via recruitment of GABA inter-
neurones, while antagonists exert a facilitatory inﬂuence (Di Giovanni
et al., 1999; Gobert et al., 2000; Invernizzi et al., 2007). Indeed,
preliminary evidence of altered dopamine signalling inC2CR transgenic
mice was obtained from an increased ratio of DA : DA metabolite
content in the cerebral cortex (P.L. Stevenson and M.C. Holmes,
unpublished data). Taken together, the hypoactivity observed in the
C2CR mice is consistent with increased 5-HT2C receptor signalling in
the frontal cortex, resulting in inhibition of dopamine release.
The role of 5-HT2C receptors in locomotor behaviour was further
investigated using pharmacological agents. 5-HT2C receptor agonists,
mCPP and RO 60-0175, decreased activity of mice in both the novel
environment of the open ﬁeld and the voluntary wheel running.
Intriguingly, the level of agonist-induced inhibition of activity did not
dramatically differ between the genotypes regardless of the distinct
receptor expression levels. Only the submaximal dose of RO 60-0175
distinguished between the genotypes; the hypoactivity induced by RO
60-0175 in the C2CR mice was greater than in the controls, the effect
reﬂecting the higher 5-HT2C receptor number in the C2CR mice.
Interestingly, the vehicle injection alone caused hypoactivity in all
mice in both the open-ﬁeld and wheel-running tests. This was
independent of the acclimatisation period as mice in wheel-running
cages showed highly reproducible running behaviour over 1 or
2 weeks in the cages yet, as soon as they were removed from the cage
for injection, the stress inhibited activity patterns following this
intervention. In some cases the transgenic mice responded to this
stress of the saline injection so severely that no further inhibition of
activity could be observed with the agonist (presumably a ﬂoor effect
due to maximal 5-HT activation of receptors in response to stress).
However, overall there was not a statistically signiﬁcant difference
between the response of the transgenic mice and the control mice. The
acute nature of these effects (within 30 min) suggests that the effect
was not mediated by increased corticosterone effects (which would
require genomic action, and > 40 min delay), but was a direct effect
on 5-HT release, or indeed other neurotransmitter pathways, in
response to the stress. The failure of the selective 5-HT2C receptor
antagonist, SB242084, to elevate activity levels in doses previously
shown to be inhibitory in vivo (Kennett et al., 1997; Hayashi et al.,
2004; Nonogaki et al., 2007) suggests that the hypoactivity was due
not to ligand activation of 5-HT2C receptors (ie. there is a low level of
endogenous 5-HT release under basal conditions) but to constitutive
activity of the 5-HT2C receptors in the C2CR mice. However,
administration of SB206553, a drug previously shown to be an inverse
agonist at 5-HT2C receptors (SB206553) in rat in vivo (De Deurw-
aerdere et al., 2004; Berg et al., 2006) and on human 5-HT2C receptors
in cell culture, did not restore hypoactivity; it instead decreased
activity of mice in both wheel-running and open-ﬁeld tests. This effect
was presumed to be independent of the drug action on 5-HT2C
receptors as similar effects, to the same degree, were also observed
in 5-HT2C receptor-deﬁcient mice (M. C. Holmes, P.L. Stevenson and
R. N. Carter, unpublished data). Hence, at present we are unable to
determine pharmacologically whether the overt behavioural phenotype
observed in the C2CR mice is as a result of increased constitutive
activity or enhanced sensitivity to the endogenous ligand of 5-HT2C
receptors. However, it is likely that the answer is a combination of the
two as the transgene only expresses the unedited form of the receptor,
which has been shown to be both constitutively active and more
sensitive to ligand than the edited forms in vitro (Niswender et al.,
1999). Interestingly, a mouse model expressing only the unedited
(INI) isoform, but at normal levels, has recently been produced
(Kawahara et al., 2008). Such mice have no overt metabolic
phenotype which would be indicative of increased signalling through
this receptor, but the consequences of this genetic manipulation on
anxiety and depressive-like behaviours has yet to be determined.
In conclusion, our animal model of unedited 5-HT2C receptor
overexpression in forebrain provides the ﬁrst evidence that an
overexpression of 5-HT2C receptors in vivo elicits a phenotype of
elevated anxiety-like behaviour and hypolocomotion, consistent with
an increased 5-HT2C receptor signalling. This model offers an
alternative method to studying 5-HT2C receptors using solely phar-
macological agents, which at present lack selective ligands. It now
becomes important to determine the molecular and cellular conse-
quences of 5-HT2C receptor overexpression and altered proﬁle
of editing, which will aid our further understanding of the function
of 5-HT2C receptors and their role in mood disorders.
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